IRCT20220720055510N1招募中2 期
The effect of Liraglutide on clinical and paraclinical symptoms in patients with polycystic ovary syndrome with high body mass index in patients referred to Shahrekord endocrinology clinics
Shahre-kord University of Medical Sciences0 个研究点目标入组 35 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 45 years（—）
- 性别
- Female
入选标准
- •Women with polycystic ovary syndrome between the ages of 18 and 45 years,
- •Written and oral consent is obtained from patients to participate in the study
- •Do not have chronic physical diseases (except polycystic ovary syndrome) and mental diseases.
- •According to the patient, there is no long-term use of drugs.
- •Body mass index is more than 25 kg/m2.
排除标准
- •suffering from other causes of hyperandrogenism such as congenital adrenal hyperplasia, Cushing's syndrome, ovarian or adrenal tumor.
- •Taking drugs that lead to side effects such as menstrual disorders, hirsutism or acne, or affect the profile of fat or blood sugar in the last 3 months, such as OCP, thiazides, corten, metformin, etc.
- •be pregnant.
- •Have a history of previous pancreatitis.
- •Have a family history of medullary thyroid carcinoma (mtc).
研究者
相似试验
进行中（未招募）
1 期
A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents (OHA's)+ high doses of insulin. - Liraglutide & Acarbose effect on HbA1c, Wt and HRQOL in type2 DiabetesType-2 Diabetes MellitusEUCTR2010-020193-42-GBHywel DdA Health Borad66
已完成
不适用
Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetesType2 diabetesJPRN-UMIN000033511Yokohama City University Medical Center Department of Endocrinology and Diabetes60
已完成
3 期
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes; A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup, multinational, multi-centre trial10018424diabetesNL-OMON38605ovo Nordisk50
进行中（未招募）
1 期
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 16.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-003580-21-NOovo Nordisk A/S1,398
进行中（未招募）
不适用
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 16.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-003580-21-SEovo Nordisk A/S1,404